Analyst Scoreboard: 14 Ratings For Halozyme Therapeutics
Portfolio Pulse from Benzinga Insights
In the last three months, 14 analysts have published ratings on Halozyme Therapeutics (NASDAQ:HALO), with a mix of bullish and neutral perspectives. The average 12-month price target is $58.14, reflecting a 3.82% increase from the previous target. Analysts have maintained or raised their ratings, with notable price target adjustments from firms like Goldman Sachs, Benchmark, and Wells Fargo. Halozyme Therapeutics has shown strong financial performance with impressive net margins and ROE, but faces higher financial risk due to its debt-to-equity ratio.
August 01, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Halozyme Therapeutics (NASDAQ:HALO) has received 14 analyst ratings in the last three months, with a majority being bullish. The average 12-month price target is $58.14, up 3.82% from the previous target. Analysts from firms like Goldman Sachs, Benchmark, and Wells Fargo have maintained or raised their ratings, indicating positive sentiment. The company has strong financial metrics but a high debt-to-equity ratio.
The majority of analysts have given bullish ratings, and the average price target has increased, indicating positive sentiment. The company's strong financial performance supports this outlook, although the high debt-to-equity ratio poses some risk.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100